Adma Biologics (ADMA) Share-based Compensation (2011 - 2026)
Adma Biologics' (ADMA) quarterly Share-based Compensation came in at $5.4 million in Q4 2025, down 0.75% YoY from $5.4 million in Q4 2024, and up 6.84% on a QoQ basis from $5.0 million in Q3 2025.
Adma Biologics (ADMA) Share-based Compensation (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 13 years of Share-based Compensation data on file, last reported at $5.4 million in Q4 2025.
- Quarterly Share-based Compensation fell 0.75% year-over-year to $5.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.0 million (up 47.08% YoY) and the FY2025 annual result came in at $20.0 million, up 47.08% from the prior year.
- Share-based Compensation climbed to $5.4 million in Q4 2025, from $5.0 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $5.4 million in Q4 2024 to a low of $688274.0 in Q3 2021.
- A 5-year average of $2.4 million and a median of $1.7 million in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation sank 32.37% — and 2024, when it jumped 211.35%.
- Tracing ADMA's Share-based Compensation over 5 years: stood at $1.2 million in 2021, then fell by 11.88% to $1.1 million in 2022, then jumped by 63.23% to $1.7 million in 2023, then jumped by 211.35% to $5.4 million in 2024, then decreased by 0.75% to $5.4 million in 2025.
- The last three Share-based Compensation figures came in at $5.4 million (Q4 2025), $5.0 million (Q3 2025), and $5.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 6.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.14 Mn |
| Jun 30, 2026 | 6.14 Mn |
| Dec 31, 2025 | 5.39 Mn |
| Dec 31, 2025 | 5.39 Mn |
| Sep 30, 2025 | 5.05 Mn |
| Sep 30, 2025 | 5.05 Mn |
| Jun 30, 2025 | 4.96 Mn |
| Jun 30, 2025 | 4.96 Mn |
| Mar 31, 2025 | 4.62 Mn |
| Mar 31, 2025 | 4.62 Mn |
| Dec 31, 2024 | 5.43 Mn |
| Dec 31, 2024 | 5.43 Mn |
| Sep 30, 2024 | 3.18 Mn |
| Sep 30, 2024 | 3.18 Mn |
| Jun 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 2.86 Mn |
| Mar 31, 2024 | 2.14 Mn |
| Mar 31, 2024 | 2.14 Mn |
| Dec 31, 2023 | 1.75 Mn |
| Dec 31, 2023 | 1.75 Mn |